Inclisiran

Half-Life (t½)
SC: 9h
Molecular Weight
17272 g/mol
Aliases
Leqvio

Pharmacological Mechanism

GalNAc-conjugated small interfering RNA. GalNAc moiety targets asialoglycoprotein receptor on hepatocytes → selective hepatic uptake. siRNA silences PCSK9 mRNA → preserves hepatic LDLR → 50% LDL reduction. Twice-yearly dosing — extraordinary convenience vs mAb PCSK9 inhibitors (every 2–4 weeks).

Half-Life & Elimination Curve (SC: 9h)

100%50%25%12.5%0%0h0×t½9h1×t½18h2×t½27h3×t½36h4×t½45h5×t½0×t½ (0h): 100% remaining (~6.49 mg/L)1×t½ (9h): 50% remaining (~3.25 mg/L)2×t½ (18h): 25% remaining (~1.62 mg/L)3×t½ (27h): 12.5% remaining (~0.811 mg/L)4×t½ (36h): 6.3% remaining (~0.406 mg/L)5×t½ (45h): 3.1% remaining (~0.203 mg/L)
Elimination (SC)
  • 0×t½0h100% (6.49 mg/L)
  • 1×t½9h50% (3.25 mg/L)
  • 2×t½18h25% (1.62 mg/L)
  • 3×t½27h12.5% (0.811 mg/L)
  • 4×t½36h6.3% (0.406 mg/L)
  • 5×t½45h3.1% (0.203 mg/L)
Elimination t½9h (SC)
Rate Constant (ke)0.077 h⁻¹
Est. Peak (Cmax)6.49 mg/L
Clearance (CL)2.7 L/h
97% Washout (5×t½)45h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Interactions

References